

Nikolay Bulanov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4305720/publications.pdf>

Version: 2024-02-01

14
papers

105
citations

1936888

4
h-index

1372195

10
g-index

15
all docs

15
docs citations

15
times ranked

137
citing authors

#	ARTICLE	IF	CITATIONS
1	Classification of systemic vasculitis: evolution from eponyms to modern criteria. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 704-708.	0.2	2
2	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	0.9	20
3	Venn diagrams and probability in clinical research. <i>SeÄenovskij Vestnik</i> , 2021, 11, 5-14.	0.3	1
4	Studies and research design in medicine. <i>SeÄenovskij Vestnik</i> , 2021, 12, 4-17.	0.3	3
5	Upper respiratory tract manifestations in patients with ANCA-associated vasculitides and their association with the presence and type of ANCA. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 555-562.	0.2	0
6	Basic principles of descriptive statistics in medical research. <i>SeÄenovskij Vestnik</i> , 2021, 12, 4-16.	0.3	3
7	Influence of Genetic Factors on Immunopathogenesis and Clinical Phenotypes of ANCA-associated Vasculitis. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 642-651.	0.2	0
8	The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis. <i>Clinical and Experimental Immunology</i> , 2020, 202, 394-402.	1.1	34
9	Lingual and digital necrosis in microscopic polyangiitis. <i>Rheumatology</i> , 2020, 59, 3582-3583.	0.9	1
10	Is There a Role for LAMP-2 Autoantibodies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis?. <i>Journal of Rheumatology</i> , 2020, 47, 636-638.	1.0	0
11	Myocardial Infarction Due to Takayasu Arteritis in Adults: Look Out for Multivascular Involvement and Signs of Systemic Inflammation. <i>Canadian Journal of Cardiology</i> , 2020, 36, 969.e11.	0.8	3
12	Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease. <i>Farmakoekonomika</i> , 2019, 11, 38-46.	0.4	0
13	Testing for antineutrophil cytoplasmic antibodies (ANCA) in patients with systemic vasculitides and other diseases. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e23-e23.	0.5	7
14	Bortezomib in refractory ANCA-associated vasculitis: a new option?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e9-e9.	0.5	25